Xcout Intel
Merus N.V. competitors & alternatives
The 12 closest competitors and alternatives to Merus N.V. among biotechnology companies — ranked by similarity to what Merus N.V. actually does, not by market-cap band.
Subscribe to see Merus N.V.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Merus N.V.
Merus N.V. is a clinical-stage oncology company that discovers and develops antibody treatments for cancer using its proprietary Multiclonics platform. The company serves patients with cancer by advancing innovative therapeutic pipelines. Merus operates as part of Genmab.
Merus N.V. at a glance
Merus N.V. is a biotechnology company headquartered in Netherlands. It has raised at least $181.3M across the 5 funding rounds on record. Its most recent funding round raised $11.5M in July 2020. Xcout tracks 4 named people at Merus N.V., including Jan G.J. van de Winkel, Ph.D. (Executive Director and Chief Executive Officer).
Merus N.V. leadership
- Jan G.J. van de Winkel, Ph.D.Executive Director and Chief Executive Officer
- Anthony PaganoNon-Executive Director
- Greg MuellerNon-Executive Director
- Martine J. van Vugt, Ph.D.Non-Executive Director
Merus N.V. funding rounds
At least $181.3M raised across the 5 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $11.5M | 5 named | |
| SEC Form D filing | $15M | — | |
| SEC Form D filing | $55.8M | — | |
| SEC Form D filing | $80M | — | |
| Series A | $19M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Merus N.V. competitors
Ranked by semantic similarity — how close each company is to Merus N.V. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Perseus Proteomics Inc. is a Japanese biotechnology company focused on antibody drug discovery and research support. The firm develops novel therapeutic antibody drugs for cancer and other diseases utilizing its proprietary antibody technologies.
Similar biotechnology company
AbbraTech Holdings LLC operates a platform technology focused on recombinant antibody discovery, engineering, and validation. The company targets human diseases such as cancer, immune disorders, and viral infections by developing antibodies for difficult-to-reach drug targets through its proprietary Epivolve technology.
Similar biotechnology company
Normunity Holding Company, LLC is a biotechnology company developing novel anti-cancer therapies and biologic medicines, including therapeutic antibodies, bispecific antibodies, and T cell engagers. The company utilizes proprietary discovery platforms originating from a partnership with the Yale School of Medicine to target mechanisms at the interface of tumors and the immune system.
Similar biotechnology company
Mestag Therapeutics is an immunotherapy company focusing on fibroblast-immune biology to address critical unmet needs in inflammatory diseases and oncology. The company operates across hubs including Cambridge, United Kingdom, and Ghent, Belgium.
Biotech
AbCellera is a biotechnology company that integrates biology, computation, and engineering to discover and develop antibody-based medicines. The company operates a proprietary technology platform to advance internal and partnered drug programs across therapeutic areas such as endocrinology, immunology, autoimmunity, and oncology.
Biotech
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Biotech
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Similar biotechnology company
Amphivena Therapeutics, Inc. is a privately held, clinical-stage biotechnology company based in South San Francisco, California. The company specializes in immuno-oncology, developing a platform of dual-function biologics and selective T cell engagers for the treatment of hematological conditions.
Similar biotechnology company
Chimagen Biosciences is a biopharmaceutical company headquartered in Shanghai, China, founded in July 2016. The company specializes in multi-specific antibody therapeutics and built the proprietary TRIAD platform for engineering.
Biotech
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Biotech
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Biotech
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Merus N.V. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Merus N.V.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →